Compare Gilead Sciences, Inc. (GILD) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs STMicroelectronics NV — how do they compare? Gilead Sciences, Inc. trades at $134.66 (market cap $163.51B), while STMicroelectronics NV trades at $62.46 (market cap $59.83B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× STMicroelectronics NV's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | STM | |
|---|---|---|
Market Cap | $163.51B | $59.83B |
Sector | Health | Financials |
52-Week High | $155.80 | $79.91 |
52-Week Low | $108.22 | $21.20 |
Enterprise Value | $178.05B | $58.04B |
Dividend Yield | 2.49% | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
STM (STMicroelectronics) trades at $63.00, down 10.17% in the past 24 hours, reflecting bearish technical momentum. The stock shows mixed fundamentals with a high P/E ratio of 423.44 and thin net income margin of 1.19%, though recent Q3 2025 earnings beat expectations. Analyst consensus remains positive with a $72.33 price target, supported by AI and automotive chip partnerships highlighted in recent news (Zacks Investment Research, July 14, 2026). Cash flow improved to $555 million in 2025, but revenue has declined from 2023 peaks.
Outlook: STM faces near-term pressure from earnings misses and high valuation, but long-term growth drivers in AI and automotive sectors offer potential upside. Key risks include competitive pressures and reliance on semiconductor cycle recovery. Institutional sentiment is cautiously optimistic with 52% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
